Belite Bio (NASDAQ:BLTE) is a biotechnology firm focused on developing therapeutic drugs for the treatment of eye diseases and metabolic disorders. Primarily operating in the research and development sector, the company is dedicated to advancing its portfolio of innovative treatments through clinical trials, with a keen eye on addressing unmet medical needs. Among its key projects are treatments aimed at tackling Age-related Macular Degeneration (AMD) and Stargardt Disease, highlighting its commitment to improving quality of life for patients with serious conditions. Belite Bio's objectives include the successful progress of their drug candidates through regulatory approvals, aiming for commercialization to make a significant impact on healthcare.